Life SciencesLiability
Get a quote

TL;DR

A multinational trial is insured country by country, not by stretching one US policy. Several regimes set conditions a US policy cannot meet by design, such as an insurer authorised locally or a territory that includes the host country. The working structure is a master policy plus locally issued policies, sized at three levels: per subject, per protocol, and in the aggregate. The local certificate goes into the ethics or regulatory dossier, so it sits on the critical path to site activation.

Phase 2b/3 · Pivotal · Multi-country

One protocol, several countries. Each one has its own insurance test.

A device sponsor running a few hundred patients across the US, the EU, and Israel does not have one insurance requirement. It has one per country, each set by a different law or ethics committee, each evidenced by a certificate that has to exist before that country’s sites can open.

This page covers how those programs are built and where they slip. For the sponsor-side basics, start with clinical trial insurance.

Request the reviewSize the trial limit

Why worldwide territory is not enough

What local rules actually ask for.

Where
What is required
Why a US policy falls short
European Union (medicinal products)
Each Member State must have a compensation system in the form of insurance, a guarantee, or an equivalent arrangement appropriate to the nature and extent of the risk. Proof is submitted per Member State concerned.
Sponsor and investigator must use the system "in the form appropriate for the Member State concerned". The form is set nationally.
Germany (medicinal products)
Subject insurance that pays even when no one else is liable, from an insurer authorised in the EU or EEA, with at least EUR 500,000 available for each death or permanent incapacity to work.
A policy from an insurer not authorised in the EU or EEA does not meet the condition, whatever its territory says.
Israel
The Ministry of Health's published draft model CTA calls for a clinical trials sub-limit of not less than US$3,000,000 per occurrence and in the aggregate, the Helsinki Committee and site staff as additional insureds, and a 7-year discovery period on claims-made forms.
The same draft requires that territory limits and jurisdiction include Israel.
United States
No federal mandate to insure. For research above minimal risk, the consent form must explain whether compensation and medical treatment are available if injury occurs.
The requirement usually arrives through the CTA and the institution, not a regulator.

Sources are listed at the foot of the page. Requirements change, and other countries on a protocol will have their own; each should be confirmed against the current local rule before submission.

01 · Program structure

A master policy on top, local policies underneath.

Each country that requires local paper gets a policy issued there, on wording the ethics committee recognises, producing the certificate the dossier needs. The master policy sits above them, written to the sponsor, and fills the gap where a local policy is narrower in scope or lower in limit than the sponsor wants. Specialty markets with local networks issue both sides so the wordings are written to fit together.

Countries without a local requirement can sit under the master directly. The decision is made country by country, and it is worth recording why each one went the way it did, because the next protocol will ask the same questions.

02 · Limit structure

Per subject, per protocol, and in the aggregate.

Three numbers do different jobs. The per-subject limit is what any one participant can access, and it is the figure local rules most often set. The per-protocol limit caps the study. The aggregate caps everything the policy covers in the period, which matters when one program insures several protocols.

They fail in combination. A per-subject figure that satisfies the strictest country can sit inside a protocol aggregate that a handful of serious events would exhaust. A shared aggregate across protocols can satisfy each certificate on paper while promising the same money several times. Size the protocol aggregate to enrollment and indication risk, then confirm each local per-subject term fits inside it.

03 · Lead time

The certificate is on the critical path to site activation.

A local certificate needs a bound local policy. A bound local policy needs underwriting: protocol, investigator brochure, safety data, enrollment by country, and site list. Local issuance adds its own steps, and where a country requires proof of insurance, the submission is not complete without it.

The common failure is sequencing. Clinical operations finishes the dossier, then asks for insurance, and the certificate becomes the last open item. Start the insurance workstream when the country list is drafted, and give underwriters the planned enrollment per country rather than a global total.

04 · Mid-study changes

New countries and amendments change the policy, not just the protocol.

Adding a country means a new local policy or endorsement and new proof of insurance. In the EU, extending an authorised trial to an additional Member State is its own application under Article 14 of the Clinical Trials Regulation, with a 52-day decision period that can be extended by up to 31 days for further information. The proof of insurance for that Member State is part of that dossier, so it must exist when the application is filed.

Protocol amendments matter as much. A change in enrollment, dose, population, or duration can fall outside a policy written to a specific protocol version and subject count. Send substantial amendments to underwriters before they take effect, and check that the local certificates still describe the protocol the sites are running.

Subject-injury regimes

Fault-based and no-fault are different promises.

A US trial liability policy pays when the insured is legally liable. A subject usually has to show negligence or a defect. Some countries go further and require cover that compensates a subject for trial-related injury whether or not anyone was at fault. Germany’s rule for drug trials is written that way: the insurance must pay even when no one else is liable for the harm.

A legal-liability form does not answer a no-fault obligation unless it is built to. That is the practical reason local policies exist: they are written on the trigger the country expects. It is also why the subject-injury language in each CTA and consent form should be read against the policy that is meant to fund it.

Device pivotal vs drug

Same architecture, different exposure.

The EU Medical Device Regulation carries its own damage compensation article for clinical investigations, worded in parallel to the drug regulation, so the local-paper question is the same. What changes is the claim profile. Device studies often include an implant or surgical procedure, and the policy should be clear on whether injury from a protocol-required procedure is covered alongside injury from the device itself.

Implant studies also run long follow-up, which pushes the reporting tail. And a pivotal device trial sits next to a commercial launch: the trial policy generally does not cover marketed product, so the products liability program needs to be in place at approval, while trial follow-up continues.

Coordination

Trial policy, CRO E&O, and CTA indemnity have to line up.

The trial policy answers injury from the product or the protocol. The CRO’s E&O answers the CRO’s own service failures, and its territory needs to reach every country the CRO operates in. The CTA indemnity is the sponsor’s contractual promise to each site, and international GCP expects it to exclude claims arising from the site’s malpractice or negligence.

Gaps open when these are bought separately. Check that the CRO is an insured on the trial policy for protocol-related claims, that the trial policy covers the contractual liability each CTA creates, and that the CTA limits and survival periods in each country match the local policy actually issued. More on the sponsor and CRO boundary.

Frequently asked

Common questions about multinational trial insurance

Does a US clinical trial policy with a worldwide territory cover our sites abroad?

It may respond to a claim, but that is a different question from whether the ethics committee or regulator in that country will accept it. Some regimes set conditions a US policy cannot meet by design. Germany, for example, requires subject insurance from an insurer authorised in the EU or EEA, and the model agreement published by the Israeli Ministry of Health requires a territory and jurisdiction that include Israel. The usual answer is a locally issued policy in each country that requires one, coordinated under a master policy.

What is the difference between a per-subject limit and a per-protocol limit?

A per-subject limit caps what is available for any one participant. A per-protocol limit caps what is available for the whole study, usually in the aggregate. Local rules and ethics committees often specify the per-subject figure, while the sponsor decides the protocol aggregate. Both have to be read together: a high per-subject limit inside a thin protocol aggregate can be exhausted by a small number of serious events.

How early should we start on local insurance certificates?

When the country list is drafted, not when sites are selected. The certificate is part of the submission dossier, and issuing it requires a bound local policy, which requires underwriting information such as the protocol, the investigator brochure, and planned enrollment by country. If insurance starts after the rest of the dossier is ready, it becomes the item that holds up site activation.

What happens when we add a country or amend the protocol mid-study?

A new country needs its own local policy or endorsement and its own proof of insurance before submission. Under the EU Clinical Trials Regulation, extending an authorised trial to an additional Member State is a separate application with its own decision period. Protocol amendments that change enrollment, dose, population, or duration should go to underwriters before they take effect, because many trial policies are written to a specific protocol and declared subject count.

Does the CRO's professional liability cover subject injury in a multinational trial?

Generally not. CRO errors and omissions cover the CRO's own services, such as monitoring or data management. Injury caused by the investigational product or a protocol procedure sits with the sponsor's trial policy. The CRO is often added as an insured on the sponsor's policy for protocol-related claims, and its own E&O territory should be checked against the country list.

Is a device pivotal trial insured differently from a drug trial?

The structure is the same, but the exposure profile differs. Device investigations often involve an implant or surgical procedure, so the line between device injury and procedure injury matters, and follow-up can be long. In the EU, the Medical Device Regulation carries its own damage compensation article for clinical investigations, parallel to the one for medicinal products. Planning also needs to cover the hand-off to commercial products liability at approval.

Next steps

Keep going.

Related deep-dives

Go deeper on the specific clauses and decisions that show up most.

Authoritative references

Primary sources cited on this page

Multinational trial review

Send the country list before the dossier is final.

Send the protocol synopsis, the country and site list with planned enrollment, and your current policies. A specialist returns a country-by-country read of what each submission needs and where the program falls short.

Request the review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.